{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:20Z","timestamp":1788279980742,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":907,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1999,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>:\u2002Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15\u2003mg and 30\u2003mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>:\u2002Fifty\u2010six patients were treated with either lansoprazole 15\u2003mg, 30\u2003mg or placebo o.m.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>:\u2002Within 1\u2003month of study initiation, 27% (four out of 15) of placebo\u2010treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15\u2003mg and 30\u2003mg treated patients, respectively. Median time to first ulcer recurrence was\u2003&gt;\u200312\u2003months in lansoprazole patients. At Month 12, significantly (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) more lansoprazole 15\u2003mg patients (70%) and lansoprazole 30\u2003mg patients (85%) remained healed. Eighty\u2010two per cent of lansoprazole 15\u2003mg and 76% of lansoprazole 30\u2003mg patients remained asymptomatic during the entire study period. All placebo patients became symptomatic, experienced ulcer recurrence, or withdrew from the study by month six. The incidence of adverse events was comparable among the three treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>:\u2002Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer\u2010related symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1999.00569.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:39:13Z","timestamp":1047353953000},"page":"959-967","source":"Crossref","is-referenced-by-count":6,"title":["Double\u2010blind comparison of lansoprazole 15\u2003mg, lansoprazole 30\u2003mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H<sub>2<\/sub>\u2010receptor antagonists"],"prefix":"10.1111","volume":"13","author":[{"family":"Kovacs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(89)80052-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342204"},{"key":"e_1_2_6_4_2","first-page":"43","article-title":"Reflux and Helicobacter pylori","volume":"13","author":"DeKoster E","year":"1997","journal-title":"Curr Op Gastroenterol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198608000-00005"},{"key":"e_1_2_6_6_2","first-page":"2","article-title":"Duodenal and gastric ulcer healing rates: a review","volume":"77","author":"Legerton CW.","year":"1984","journal-title":"Am J Med"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90815-I"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.10.1458"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1992.tb00541.x"},{"key":"e_1_2_6_10_2","unstructured":"SollAH.Gastric duodenal and stress ulcer. In: Sleisenger M Fordtran J eds. Gastrointestinal Disease: Pathophysiology\/Diagnosis\/Management. Philadelphia: Saunders 1993: 580\u2013679."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01298864"},{"key":"e_1_2_6_12_2","first-page":"1289","article-title":"Possible mechanisms for the inhibition of acid formation by the proton pump inhibitor AG\u20101749 in isolated canine parietal cells","volume":"252","author":"Nagaya H","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00582.x"},{"key":"e_1_2_6_14_2","first-page":"A172","article-title":"Gastric pH levels after 15\u2003mg and 30\u2003mg of lansoprazole and 20\u2003mg omeprazole","volume":"106","author":"Tolman KG","year":"1994","journal-title":"Gastroenterology"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1989.tb00205.x"},{"key":"e_1_2_6_16_2","first-page":"1191","article-title":"Double\u2010blind comparison of lansoprazole, ranitidine and placebo in the treatment of acute duodenal ulcer","volume":"89","author":"Lanza F","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_17_2","first-page":"334","article-title":"Comparaison du lansoprazole (30\u2003mg) et de l\u2019omeprazole (20\u2003mg) dans le traitement de l\u2019ulcer duodenal. Esais therapeutiques multicentriques comparatif en double aveugle","volume":"17","author":"Petite JP","year":"1993","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_6_18_2","first-page":"210","article-title":"Lansoprazole vs omeprazole in active ulcer: a healing study","volume":"30","author":"Ekstrom P","year":"1995","journal-title":"Gastroenterology"},{"key":"e_1_2_6_19_2","first-page":"A122","article-title":"Lansoprazole for one year prevents recurrence of duodenal ulcer","volume":"106","author":"Lanza F","year":"1994","journal-title":"Gastroenterology"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)90895-0"},{"key":"e_1_2_6_21_2","first-page":"175","article-title":"Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer","volume":"122","author":"Misawa T","year":"1991","journal-title":"Ther Res"},{"key":"e_1_2_6_22_2","first-page":"933","article-title":"Clinical study of AG\u20101749 (lansoprazole): effects on serum gastrin levels and gastric mucosal ECL cell density","volume":"19","author":"Ogoshi K","year":"1991","journal-title":"Yakuri Chiryo"},{"key":"e_1_2_6_23_2","first-page":"A74","article-title":"Evaluation of enterochromaffin\u2010like (ECL) cell hyperplasia during long\u2010term treatment with the proton pump inhibitor lansoprazole","volume":"104","author":"Eissele R","year":"1993","journal-title":"Gastroenterology"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000199786"},{"key":"e_1_2_6_25_2","first-page":"65","article-title":"Consensus Conference Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease","volume":"272","author":"NIH","year":"1994","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402103300602"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00589.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1987.tb00608.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1990.tb00491.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1999.00569.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1999.00569.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1999.00569.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T16:27:20Z","timestamp":1698510440000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1999.00569.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1999,7]]}},"alternative-id":["10.1046\/j.1365-2036.1999.00569.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1999.00569.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,7]]}}}